甘李药业：关于GZR102注射液Ⅱ期临床试验完成首例受试者给药的公告

Group 1 - The core point of the article is that Gannee Pharmaceutical announced the initiation of Phase II clinical trials for its self-developed GZR102 injection in China, with the first patient successfully dosed recently [2] Group 2 - Gannee Pharmaceutical's wholly-owned subsidiary, Gannee Pharmaceutical Shandong Co., Ltd., is responsible for the development of GZR102 injection [2] - The announcement was made on the evening of August 8 [2]